Cargando…

Docking and quantitative structure–activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors

PDE3s belong to the phosphodiesterases family, where the PDE3A isoform is the major subtype in platelets involved in the cAMP regulation pathway of platelet aggregation. PDE3A inhibitors have been designed as potential antiplatelet agents. In this work, a homology model of PDE3A was developed and us...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz-Gutiérrez, Camila, Cáceres-Rojas, Daniela, Adasme-Carreño, Francisco, Palomo, Iván, Fuentes, Eduardo, Caballero, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720733/
https://www.ncbi.nlm.nih.gov/pubmed/29216268
http://dx.doi.org/10.1371/journal.pone.0189213
_version_ 1783284716695191552
author Muñoz-Gutiérrez, Camila
Cáceres-Rojas, Daniela
Adasme-Carreño, Francisco
Palomo, Iván
Fuentes, Eduardo
Caballero, Julio
author_facet Muñoz-Gutiérrez, Camila
Cáceres-Rojas, Daniela
Adasme-Carreño, Francisco
Palomo, Iván
Fuentes, Eduardo
Caballero, Julio
author_sort Muñoz-Gutiérrez, Camila
collection PubMed
description PDE3s belong to the phosphodiesterases family, where the PDE3A isoform is the major subtype in platelets involved in the cAMP regulation pathway of platelet aggregation. PDE3A inhibitors have been designed as potential antiplatelet agents. In this work, a homology model of PDE3A was developed and used to obtain the binding modes of bicyclic heteroaromatic pyridazinones and pyrazolones. Most of the studied compounds adopted similar orientations within the PDE3A active site, establishing hydrogen bonds with catalytic amino acids. Besides, the structure-activity relationship of the studied inhibitors was described by using a field-based 3D-QSAR method. Different structure alignment strategies were employed, including template-based and docking-based alignments. Adequate correlation models were obtained according to internal and external validations. In general, QSAR models revealed that steric and hydrophobic fields describe the different inhibitory activities of the compounds, where the hydrogen bond donor and acceptor fields have minor contributions. It should be stressed that structural elements of PDE3A inhibitors are reported here, through descriptions of their binding interactions and their differential affinities. In this sense, the present results could be useful in the future design of more specific and potent PDE3A inhibitors that may be used for the treatment of cardiovascular diseases.
format Online
Article
Text
id pubmed-5720733
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-57207332017-12-15 Docking and quantitative structure–activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors Muñoz-Gutiérrez, Camila Cáceres-Rojas, Daniela Adasme-Carreño, Francisco Palomo, Iván Fuentes, Eduardo Caballero, Julio PLoS One Research Article PDE3s belong to the phosphodiesterases family, where the PDE3A isoform is the major subtype in platelets involved in the cAMP regulation pathway of platelet aggregation. PDE3A inhibitors have been designed as potential antiplatelet agents. In this work, a homology model of PDE3A was developed and used to obtain the binding modes of bicyclic heteroaromatic pyridazinones and pyrazolones. Most of the studied compounds adopted similar orientations within the PDE3A active site, establishing hydrogen bonds with catalytic amino acids. Besides, the structure-activity relationship of the studied inhibitors was described by using a field-based 3D-QSAR method. Different structure alignment strategies were employed, including template-based and docking-based alignments. Adequate correlation models were obtained according to internal and external validations. In general, QSAR models revealed that steric and hydrophobic fields describe the different inhibitory activities of the compounds, where the hydrogen bond donor and acceptor fields have minor contributions. It should be stressed that structural elements of PDE3A inhibitors are reported here, through descriptions of their binding interactions and their differential affinities. In this sense, the present results could be useful in the future design of more specific and potent PDE3A inhibitors that may be used for the treatment of cardiovascular diseases. Public Library of Science 2017-12-07 /pmc/articles/PMC5720733/ /pubmed/29216268 http://dx.doi.org/10.1371/journal.pone.0189213 Text en © 2017 Muñoz-Gutiérrez et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Muñoz-Gutiérrez, Camila
Cáceres-Rojas, Daniela
Adasme-Carreño, Francisco
Palomo, Iván
Fuentes, Eduardo
Caballero, Julio
Docking and quantitative structure–activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors
title Docking and quantitative structure–activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors
title_full Docking and quantitative structure–activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors
title_fullStr Docking and quantitative structure–activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors
title_full_unstemmed Docking and quantitative structure–activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors
title_short Docking and quantitative structure–activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors
title_sort docking and quantitative structure–activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3a (pde3a) inhibitors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720733/
https://www.ncbi.nlm.nih.gov/pubmed/29216268
http://dx.doi.org/10.1371/journal.pone.0189213
work_keys_str_mv AT munozgutierrezcamila dockingandquantitativestructureactivityrelationshipofbicyclicheteroaromaticpyridazinoneandpyrazolonederivativesasphosphodiesterase3apde3ainhibitors
AT caceresrojasdaniela dockingandquantitativestructureactivityrelationshipofbicyclicheteroaromaticpyridazinoneandpyrazolonederivativesasphosphodiesterase3apde3ainhibitors
AT adasmecarrenofrancisco dockingandquantitativestructureactivityrelationshipofbicyclicheteroaromaticpyridazinoneandpyrazolonederivativesasphosphodiesterase3apde3ainhibitors
AT palomoivan dockingandquantitativestructureactivityrelationshipofbicyclicheteroaromaticpyridazinoneandpyrazolonederivativesasphosphodiesterase3apde3ainhibitors
AT fuenteseduardo dockingandquantitativestructureactivityrelationshipofbicyclicheteroaromaticpyridazinoneandpyrazolonederivativesasphosphodiesterase3apde3ainhibitors
AT caballerojulio dockingandquantitativestructureactivityrelationshipofbicyclicheteroaromaticpyridazinoneandpyrazolonederivativesasphosphodiesterase3apde3ainhibitors